Increasing antibody affinity by altering glycosylation of immunoglobulin variable region
    1.
    发明授权
    Increasing antibody affinity by altering glycosylation of immunoglobulin variable region 失效
    通过改变免疫球蛋白可变区的糖基化增加抗体亲和力

    公开(公告)号:US06933368B2

    公开(公告)日:2005-08-23

    申请号:US10084825

    申请日:2002-02-25

    CPC分类号: C07K16/00 C07K16/2896

    摘要: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.

    摘要翻译: 本发明提供用于产生突变改变的免疫球蛋白的方法和含有这种突变改变的免疫球蛋白的组合物,其中所述突变改变的免疫球蛋白具有至少一个突变,其改变可变区中的糖基化模式,从而改变免疫球蛋白的亲和力 预选抗原。 本发明的方法和组合物提供对抗原具有增加的亲和力的免疫球蛋白。 这种糖基化改变的免疫球蛋白适用于诊断和治疗应用。

    Antibodies with increased binding affinity
    2.
    发明授权
    Antibodies with increased binding affinity 失效
    具有增加的结合亲和力的抗体

    公开(公告)号:US06350861B1

    公开(公告)日:2002-02-26

    申请号:US08862871

    申请日:1997-05-23

    IPC分类号: C07K1630

    CPC分类号: C07K16/00 C07K16/2896

    摘要: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.

    摘要翻译: 本发明提供用于产生突变改变的免疫球蛋白的方法和含有这种突变改变的免疫球蛋白的组合物,其中所述突变改变的免疫球蛋白具有至少一个突变,其改变可变区中的糖基化模式,从而改变免疫球蛋白的亲和力 预选抗原。 本发明的方法和组合物提供对抗原具有增加的亲和力的免疫球蛋白。 这种糖基化改变的免疫球蛋白适用于诊断和治疗应用。

    Increasing antibody affinity by altering glycosylation in the
immunoglobulin variable region
    3.
    发明授权
    Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region 失效
    通过改变免疫球蛋白可变区中的糖基化增加抗体亲和力

    公开(公告)号:US5714350A

    公开(公告)日:1998-02-03

    申请号:US372262

    申请日:1995-01-13

    CPC分类号: C07K16/00 C07K16/2896

    摘要: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.

    摘要翻译: 本发明提供用于产生突变改变的免疫球蛋白的方法和含有这种突变改变的免疫球蛋白的组合物,其中所述突变改变的免疫球蛋白具有至少一个突变,其改变可变区中的糖基化模式,从而改变免疫球蛋白的亲和力 预选抗原。 本发明的方法和组合物提供对抗原具有增加的亲和力的免疫球蛋白。 这种糖基化改变的免疫球蛋白适用于诊断和治疗应用。

    Humanized immunoglobulins
    5.
    发明申请
    Humanized immunoglobulins 审中-公开
    人源化免疫球蛋白

    公开(公告)号:US20080160018A1

    公开(公告)日:2008-07-03

    申请号:US11603273

    申请日:2006-11-20

    摘要: Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

    摘要翻译: 提供了具有一个或多个互补决定区(CDR)和来自供体免疫球蛋白的可能的附加氨基酸和来自接受人免疫球蛋白的框架区的人源化免疫球蛋白的生产和组合物的新方法。 除了CDR之外,每个人源化免疫球蛋白链通常还包含来自供体免疫球蛋白框架的氨基酸,例如能够与CDR相互作用以产生结合亲和力,例如一个或多个氨基酸,其紧邻于 供体免疫球蛋白中的CDR或通过分子建模预测的那些。 重链和轻链各自可以通过使用各种位置标准中的任何一个或全部来设计。 当组合成完整的抗体时,本发明的人源化免疫球蛋白在人体中将基本上是非免疫原性的,并且保留与抗原例如含有表位的蛋白质或其它化合物基本上与供体免疫球蛋白相同的亲和力。